Lizcano-Meneses, S.; Hernández-Pando, R.; García-Aguirre, I.; Bonilla-Delgado, J.; Alvarado-Castro, V.M.; Cisneros, B.; Gariglio, P.; Cortés-Malagón, E.M.
Combined Inhibition of Indolamine-2,3-Dioxygenase 1 and C-X-C Chemokine Receptor Type 2 Exerts Antitumor Effects in a Preclinical Model of Cervical Cancer. Biomedicines 2023, 11, 2280.
https://doi.org/10.3390/biomedicines11082280
AMA Style
Lizcano-Meneses S, Hernández-Pando R, García-Aguirre I, Bonilla-Delgado J, Alvarado-Castro VM, Cisneros B, Gariglio P, Cortés-Malagón EM.
Combined Inhibition of Indolamine-2,3-Dioxygenase 1 and C-X-C Chemokine Receptor Type 2 Exerts Antitumor Effects in a Preclinical Model of Cervical Cancer. Biomedicines. 2023; 11(8):2280.
https://doi.org/10.3390/biomedicines11082280
Chicago/Turabian Style
Lizcano-Meneses, Solangy, Rogelio Hernández-Pando, Ian García-Aguirre, José Bonilla-Delgado, Víctor Manuel Alvarado-Castro, Bulmaro Cisneros, Patricio Gariglio, and Enoc Mariano Cortés-Malagón.
2023. "Combined Inhibition of Indolamine-2,3-Dioxygenase 1 and C-X-C Chemokine Receptor Type 2 Exerts Antitumor Effects in a Preclinical Model of Cervical Cancer" Biomedicines 11, no. 8: 2280.
https://doi.org/10.3390/biomedicines11082280
APA Style
Lizcano-Meneses, S., Hernández-Pando, R., García-Aguirre, I., Bonilla-Delgado, J., Alvarado-Castro, V. M., Cisneros, B., Gariglio, P., & Cortés-Malagón, E. M.
(2023). Combined Inhibition of Indolamine-2,3-Dioxygenase 1 and C-X-C Chemokine Receptor Type 2 Exerts Antitumor Effects in a Preclinical Model of Cervical Cancer. Biomedicines, 11(8), 2280.
https://doi.org/10.3390/biomedicines11082280
